Corryn Biotechnologies

Corryn Biotechnologies

Private
Port TalbotEnergy & Sustainabilityhttps://corryn.co.uk

Last Round

Early Funding

Apr 2, 2026

Total Funding Raised

$1.89M

Momentum Score

25 /100

Company Overview

Corryn Biotechnologies is a medical technology company developing a handheld device to fabricate and deposit biomimetic fibrous wound dressings directly upon wound sites at the point of care.

Sector

Energy & Sustainability

Verticals

Biotechnology, Sustainable Materials

Business Model

B2B

Customer Profile

Hardware + Subscription, Government Contracts, Services & Consulting

AI Layer

Non-AI

Keywords

biopesticidespeptide biopesticidecrop protectionbiocontrolagricultural biotechnologyagri-biotechagtechsustainable agriculturepeptide platformchemical pesticide alternativeinsect hormone disruptionbiodegradable pesticidenon-toxic pesticide

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Corryn Biotechnologies Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Corryn Biotechnologies Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Early FundingApr 2, 2026
SeedSep 25, 2024
GrantMay 14, 2024
GrantJul 3, 2023
GrantJul 7, 2021

Key People

Founding team and executive leadership

Fabio Zomer Volpato

Co-Founder And Chief Operations Officer

Founding Team

Luke Burke

Chief Executive Officer

Executive Team

Corryn Biotechnologies Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 2, 2026

    $635K raised in early funding.

  • Apr 2, 2026

    Expanded operations to the UK, Northern Europe, and Europe.

Corryn Biotechnologies Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Corryn Biotechnologies Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Corryn Biotechnologies's valuation, stock price, and market status.

Firmographic Details

HeadquartersPort Talbot
Employee Range4
Year Founded2021
Last FundingApr 2, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.